Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro

<strong>Objectives<br></strong> Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-C...

Full description

Bibliographic Details
Main Authors: Nyagwange, J, Kutima, B, Mwai, K, Karanja, HK, Gitonga, JN, Mugo, D, Sein, Y, Wright, D, Omuoyo, DO, Nyiro, JU, Tuju, J, Nokes, DJ, Agweyu, A, Bejon, P, Ochola-Oyier, LI, Scott, JAG, Lambe, T, Nduati, E, Agoti, C, Warimwe, GM
Format: Journal article
Language:English
Published: Elsevier 2022
_version_ 1826310707085312000
author Nyagwange, J
Kutima, B
Mwai, K
Karanja, HK
Gitonga, JN
Mugo, D
Sein, Y
Wright, D
Omuoyo, DO
Nyiro, JU
Tuju, J
Nokes, DJ
Agweyu, A
Bejon, P
Ochola-Oyier, LI
Scott, JAG
Lambe, T
Nduati, E
Agoti, C
Warimwe, GM
author_facet Nyagwange, J
Kutima, B
Mwai, K
Karanja, HK
Gitonga, JN
Mugo, D
Sein, Y
Wright, D
Omuoyo, DO
Nyiro, JU
Tuju, J
Nokes, DJ
Agweyu, A
Bejon, P
Ochola-Oyier, LI
Scott, JAG
Lambe, T
Nduati, E
Agoti, C
Warimwe, GM
author_sort Nyagwange, J
collection OXFORD
description <strong>Objectives<br></strong> Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-CoV-2 spike reactive and nonreactive immunoglobulin (Ig)G and IgA antibodies in prepandemic samples. <br><strong>Methods<br></strong> To investigate the presence of pre-existing immunity, we performed enzyme-linked immunosorbent assay using spike antigens from reference SARS-CoV-2, HCoV HKU1, OC43, NL63, and 229E using prepandemic samples from Kilifi in coastal Kenya. In addition, we performed neutralization assays using pseudotyped reference SARS-CoV-2 to determine the functionality of the identified reactive antibodies. <br><strong>Results<br></strong> We demonstrate the presence of HCoV serum IgG and mucosal IgA antibodies, which cross-react with the SARS-CoV-2 spike. We show pseudotyped reference SARS-CoV-2 neutralization by prepandemic serum, with a mean infective dose 50 of 1: 251, which is 10-fold less than that of the pooled convalescent sera from patients with COVID-19 but still within predicted protection levels. The prepandemic naso-oropharyngeal fluid neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1: 5.9 in the neutralization assay. <br><strong>Conclusion<br></strong> Our data provide evidence for pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya and adds to data showing pre-existing immunity for COVID-19 from other regions.
first_indexed 2024-03-07T07:55:58Z
format Journal article
id oxford-uuid:620bb9af-16e2-4e6f-aa52-db81b200f038
institution University of Oxford
language English
last_indexed 2024-03-07T07:55:58Z
publishDate 2022
publisher Elsevier
record_format dspace
spelling oxford-uuid:620bb9af-16e2-4e6f-aa52-db81b200f0382023-08-17T11:36:11ZSerum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitroJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:620bb9af-16e2-4e6f-aa52-db81b200f038EnglishSymplectic ElementsElsevier2022Nyagwange, JKutima, BMwai, KKaranja, HKGitonga, JNMugo, DSein, YWright, DOmuoyo, DONyiro, JUTuju, JNokes, DJAgweyu, ABejon, POchola-Oyier, LIScott, JAGLambe, TNduati, EAgoti, CWarimwe, GM<strong>Objectives<br></strong> Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-CoV-2 spike reactive and nonreactive immunoglobulin (Ig)G and IgA antibodies in prepandemic samples. <br><strong>Methods<br></strong> To investigate the presence of pre-existing immunity, we performed enzyme-linked immunosorbent assay using spike antigens from reference SARS-CoV-2, HCoV HKU1, OC43, NL63, and 229E using prepandemic samples from Kilifi in coastal Kenya. In addition, we performed neutralization assays using pseudotyped reference SARS-CoV-2 to determine the functionality of the identified reactive antibodies. <br><strong>Results<br></strong> We demonstrate the presence of HCoV serum IgG and mucosal IgA antibodies, which cross-react with the SARS-CoV-2 spike. We show pseudotyped reference SARS-CoV-2 neutralization by prepandemic serum, with a mean infective dose 50 of 1: 251, which is 10-fold less than that of the pooled convalescent sera from patients with COVID-19 but still within predicted protection levels. The prepandemic naso-oropharyngeal fluid neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1: 5.9 in the neutralization assay. <br><strong>Conclusion<br></strong> Our data provide evidence for pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya and adds to data showing pre-existing immunity for COVID-19 from other regions.
spellingShingle Nyagwange, J
Kutima, B
Mwai, K
Karanja, HK
Gitonga, JN
Mugo, D
Sein, Y
Wright, D
Omuoyo, DO
Nyiro, JU
Tuju, J
Nokes, DJ
Agweyu, A
Bejon, P
Ochola-Oyier, LI
Scott, JAG
Lambe, T
Nduati, E
Agoti, C
Warimwe, GM
Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title_full Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title_fullStr Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title_full_unstemmed Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title_short Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
title_sort serum igg and mucosal iga antibodies from pre pandemic samples collected in kilifi kenya neutralize sars cov 2 in vitro
work_keys_str_mv AT nyagwangej serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT kutimab serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT mwaik serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT karanjahk serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT gitongajn serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT mugod serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT seiny serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT wrightd serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT omuoyodo serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT nyiroju serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT tujuj serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT nokesdj serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT agweyua serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT bejonp serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT ocholaoyierli serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT scottjag serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT lambet serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT nduatie serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT agotic serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro
AT warimwegm serumiggandmucosaligaantibodiesfromprepandemicsamplescollectedinkilifikenyaneutralizesarscov2invitro